1.
Clin Infect Dis
; 61(3): 476-9, 2015 Aug 01.
Article
in English
| MEDLINE
| ID: mdl-25917636
ABSTRACT
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Nevirapine/therapeutic use , Adolescent , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/adverse effects , Child , Child, Preschool , Delayed-Action Preparations , Drug-Related Side Effects and Adverse Reactions/epidemiology , Follow-Up Studies , HIV Infections/epidemiology , Humans , Medication Adherence/statistics & numerical data , Nevirapine/administration & dosage , Nevirapine/adverse effects
2.
Clin Infect Dis
; 47(7): 984-5, 2008 Oct 01.
Article
in English
| MEDLINE
| ID: mdl-18778234
